{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:56:59Z","timestamp":1793735819830,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Blodcancerfonden, the Cancer Research Foundations of Radiumhemmet"},{"name":"\u00c5ke Olsson Foundation for Hematologic Research, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet"},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41375-020-0909-7","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T17:02:53Z","timestamp":1592326973000},"page":"476-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Risk of infections in patients with myeloproliferative neoplasms\u2014a population-based cohort study of 8363 patients"],"prefix":"10.1038","volume":"35","author":[{"given":"Anna Ravn","family":"Landtblom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese M-L","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W","family":"Dickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgul","family":"Batyrbekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"909_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica."},{"key":"909_CR2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/cir492","volume":"53","author":"A Safdar","year":"2011","unstructured":"Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798\u2013806.","journal-title":"Clin Infect Dis."},{"key":"909_CR3","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","volume":"28","author":"SL Goldberg","year":"2010","unstructured":"Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847\u201352.","journal-title":"J Clin Oncol."},{"key":"909_CR4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","volume":"30","author":"T Barbui","year":"2016","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30:453\u20139.","journal-title":"Blood Rev"},{"key":"909_CR5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","volume":"287","author":"M Hultcrantz","year":"2020","unstructured":"Hultcrantz M, Ravn Landtblom A, Andreasson B, Samuelsson J, Dickman PW, Kristinsson SY, et al. Incidence of myeloproliferative neoplasms\u2014trends by subgroup and age in a population-based study in Sweden. J Intern Med. 2020;287:448\u201354.","journal-title":"J Intern Med"},{"key":"909_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.beha.2014.07.003","volume":"27","author":"M Bjorkholm","year":"2014","unstructured":"Bjorkholm M, Hultcrantz M, Derolf AR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pr Res Clin Haematol. 2014;27:141\u201353.","journal-title":"Best Pr Res Clin Haematol."},{"key":"909_CR7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/L18-0245","volume":"169","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bjorkholm M, Landgren O, Kristinsson SY, Andersson TML. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms. Ann Intern Med. 2018;169:268.","journal-title":"Ann Intern Med."},{"key":"909_CR8","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995\u20133001.","journal-title":"J Clin Oncol."},{"key":"909_CR9","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","volume":"32","author":"AR Landtblom","year":"2018","unstructured":"Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Bjorkholm M, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32:2203\u201310.","journal-title":"Leukemia"},{"key":"909_CR10","doi-asserted-by":"crossref","unstructured":"Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, et al. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematol Oncol. 2018. https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/hon.2509.","DOI":"10.1002\/hon.2509"},{"key":"909_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","volume":"92","author":"N Polverelli","year":"2017","unstructured":"Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017;92:37\u201341.","journal-title":"Am J Hematol."},{"key":"909_CR12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/TCRM.S121683","volume":"13","author":"P Manduzio","year":"2017","unstructured":"Manduzio P. Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor. Ther Clin Risk Manag. 2017;13:169\u201377.","journal-title":"Ther Clin Risk Manag."},{"key":"909_CR13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijid.2019.01.002","volume":"80","author":"S Lescuyer","year":"2019","unstructured":"Lescuyer S, Ledoux MP, Gravier S, Natarajan-Ame S, Duval C, Maloisel F, et al. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. Int J Infect Dis. 2019;80:134\u20136.","journal-title":"Int J Infect Dis."},{"key":"909_CR14","first-page":"87","volume":"22","author":"A Hirano","year":"2017","unstructured":"Hirano A, Yamasaki M, Saito N, Iwato K, Daido W, Funaishi K, et al. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. Respir Med Case Rep. 2017;22:87\u201390.","journal-title":"Respir Med Case Rep."},{"key":"909_CR15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-018-3242-8","volume":"97","author":"P Sylvine","year":"2018","unstructured":"Sylvine P, Thomas S, Pirayeh E. French network of regional pharmacovigilance C. Infections associated with ruxolitinib: study in the French Pharmacovigilance database. Ann Hematol. 2018;97:913\u20134.","journal-title":"Ann Hematol"},{"key":"909_CR16","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","volume":"33","author":"M Hultcrantz","year":"2015","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf AR, Eloranta S, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden Between 1973 and 2005: A population-based study. J Clin Oncol. 2015;33:2288\u201395.","journal-title":"J Clin Oncol"},{"key":"909_CR17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659\u201367.","journal-title":"Eur J Epidemiol."},{"key":"909_CR18","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.22912","volume":"121","author":"I Turesson","year":"2007","unstructured":"Turesson I, Linet MS, Bjorkholm M, Kristinsson SY, Goldin LR, Caporaso NE, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121:2260\u20136.","journal-title":"Int J Cancer."},{"key":"909_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncologica. 2009;48:27\u201333.","journal-title":"Acta Oncologica"},{"key":"909_CR20","unstructured":"Socialstyrelsen. Cancer incidence in Sweden 2014. www.socialstyrelsen.se; 2015 2014-12-26."},{"key":"909_CR21","first-page":"339","volume":"12","author":"NI Berlin","year":"1975","unstructured":"Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339\u201351.","journal-title":"Semin Hematol"},{"key":"909_CR22","unstructured":"Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008. 439 p. p."},{"key":"909_CR23","unstructured":"Jaffe ES, World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon Oxford: IARC Press; Oxford University Press (distributor); 2001. 351."},{"key":"909_CR24","unstructured":"Socialstyrelsen. D\u00f6dsorsaksstatistik - Historik, produktionsmetoder och tillf\u00f6rlitlighet. In: Socialstyrelsen, editor. 2010."},{"key":"909_CR25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765\u201373.","journal-title":"Eur J Epidemiol"},{"key":"909_CR26","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health."},{"key":"909_CR27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"909_CR28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125\u201336.","journal-title":"Eur J Epidemiol"},{"key":"909_CR29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","volume":"14","author":"LF Mendez Luque","year":"2019","unstructured":"Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG. Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression. and symptoms. Curr Hematologic Malignancy Rep. 2019;14:145\u201353.","journal-title":"Curr Hematologic Malignancy Rep."},{"key":"909_CR30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","volume":"9","author":"G Barosi","year":"2014","unstructured":"Barosi G. An immune dysregulation in MPN. Curr Hematologic Malignancy Rep. 2014;9:331\u20139.","journal-title":"Curr Hematologic Malignancy Rep."},{"key":"909_CR31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/ejh.13292","volume":"103","author":"AL Sorensen","year":"2019","unstructured":"Sorensen AL, Bjorn ME, Riley CH, Holmstrom M, Andersen MH, Svane IM, et al. B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-alpha2, or combination treatment. Eur J Haematol. 2019;103:351\u201361.","journal-title":"Eur J Haematol."},{"key":"909_CR32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","volume":"136","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136:745\u201351.","journal-title":"Br J Haematol."},{"key":"909_CR33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/10428194.2017.1359743","volume":"59","author":"L Kjaer","year":"2018","unstructured":"Kjaer L, Holmstrom MO, Cordua S, Andersen MH, Svane IM, Thomassen M, et al. Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. Leuk Lymphoma. 2018;59:973\u20137.","journal-title":"Leuk Lymphoma"},{"key":"909_CR34","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","volume":"25","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007;25:2358\u201362.","journal-title":"Stem Cells."},{"key":"909_CR35","doi-asserted-by":"crossref","first-page":"e1345402","DOI":"10.1080\/2162402X.2017.1345402","volume":"6","author":"M Romano","year":"2017","unstructured":"Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, et al. Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. Oncoimmunology. 2017;6:e1345402.","journal-title":"Oncoimmunology."},{"key":"909_CR36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317\u201325.","journal-title":"Ann Intern Med."},{"key":"909_CR37","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","volume":"95","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95:1216\u201320.","journal-title":"Haematologica."},{"key":"909_CR38","unstructured":"Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis http:\/\/nmpn.org\/index.php\/guidelines\/17-nmpn-care-program-2017\/file: Nordic MPN Study Group; 2017. http:\/\/nmpn.org\/index.php\/guidelines\/17-nmpn-care-program-2017\/file."},{"key":"909_CR39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1600-0609.2005.00424.x","volume":"74","author":"B Andreasson","year":"2005","unstructured":"Andreasson B, Lofvenberg E, Westin J. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. Eur J Haematol. 2005;74:489\u201395.","journal-title":"Eur J Haematol"},{"key":"909_CR40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93:339\u201347.","journal-title":"Am J Hematol."},{"key":"909_CR41","doi-asserted-by":"crossref","unstructured":"Tremblay D, King A, Li L, Moshier E, Coltoff A, Koshy A, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leukemia & Lymphoma. 2020;61:660\u20137.","DOI":"10.1080\/10428194.2019.1688323"},{"key":"909_CR42","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192\u2013202.","journal-title":"Blood."},{"key":"909_CR43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","volume":"28","author":"M Massa","year":"2014","unstructured":"Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28:449\u201351.","journal-title":"Leukemia."},{"key":"909_CR44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.13519","volume":"171","author":"C Keohane","year":"2015","unstructured":"Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171:60\u201373.","journal-title":"Br J Haematol."},{"key":"909_CR45","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"K Schonberg","year":"2015","unstructured":"Schonberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187\u201399.","journal-title":"Cancer Res"},{"key":"909_CR46","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"S Parampalli Yajnanarayana","year":"2015","unstructured":"Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J, et al. JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169:824\u201333.","journal-title":"Br J Haematol."},{"key":"909_CR47","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1080\/14656566.2016.1241237","volume":"17","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Kubo S, Iwata S, Tanaka Y. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2016;17:2215\u201325.","journal-title":"Expert Opin Pharmacother"},{"key":"909_CR48","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","volume":"76","author":"R Shreberk-Hassidim","year":"2017","unstructured":"Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76:745\u201353e19.","journal-title":"J Am Acad Dermatol"},{"key":"909_CR49","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood. 2014;123:3832\u201342.","journal-title":"Blood."},{"key":"909_CR50","doi-asserted-by":"crossref","first-page":"e109799","DOI":"10.1371\/journal.pone.0109799","volume":"9","author":"J Choi","year":"2014","unstructured":"Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, et al. Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9:e109799.","journal-title":"PLoS One."},{"key":"909_CR51","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/leu.2015.218","volume":"30","author":"F Perner","year":"2016","unstructured":"Perner F, Schnoder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, et al. Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. Leukemia. 2016;30:991\u20135.","journal-title":"Leukemia."},{"key":"909_CR52","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"A Mullally","year":"2020","unstructured":"Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020;4:1792\u2013800.","journal-title":"Blood Adv."},{"key":"909_CR53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.vaccine.2017.12.019","volume":"36","author":"P Jorgensen","year":"2018","unstructured":"Jorgensen P, Mereckiene J, Cotter S, Johansen K, Tsolova S, Brown C. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008\/2009 to 2014\/2015. Vaccine. 2018;36:442\u201352.","journal-title":"Vaccine."},{"key":"909_CR54","unstructured":"Eurostat. Hospital beds. ec.europa.eu2020."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0909-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0909-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0909-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:01Z","timestamp":1684618861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0909-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0909-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"28 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andersson, Smedby, Eloranta, and Bj\u00f6rkholm\u00a0are involved in an ongoing public-private real world evidence collaboration between Karolinska Institutet and Janssen Pharmaceuticals, however, the current project is not related to this collaboration. Hultcrantz has received honoraria from Intellisphere, LLC, not related to this project. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}